Learning Objectives

Upon completing the module Antiretroviral Rx: Adverse Effects, participants should be able to:

Discuss the incidence and timing of the abacavir (Ziagen) hypersensitivity reaction and the genetic predisposition to develop this adverse reaction.
Recognize the clinical manifestations associated with the abacavir hypersensitivity reaction.
Summarize risk factors associated with an increased risk of developing nevirapine (Viramune)-associated hepatotoxicity.
Discuss the management of nevirapine (Viramune)-associated hepatotoxicity.
Describe the different types of urinary tract abnormalities that can occur when taking indinavir (Crixivan).
Discuss the prevention and management of indinavir-associated nephrotoxicity.
Identify factors that increase the risk of developing didanosine (Videx, Videx-EC)-associated pancreatitis.
Understand the interaction that occurs between tenofovir (Viread) and didanosine that causes increased didanosine levels.
List the major factors associated with the development of lactic acidemia.
Understand how alterations in normal mitochondrial function relate to the development of lactic acidemia.
Describe the mechanism for indinavir and atazanavir-associated hyperbilirubinemia.
Summarize the incidence and clinical significance of indinavir and atazanavir-associated hyperbilirubinemia.
Discuss the spectrum and timing of neuropsychiatric manifestations assocated with efavirenz (Sustiva) use.
Understand prevention and managment strategies to minimize efavirenz-related neuropsychiatric complications.